Premium
The muscle‐hypertrophic effect of clenbuterol is additive to the hypertrophic effect of myostatin suppression
Author(s) -
Kim Kyung Ho,
Kim Yong Soo,
Yang Jinzeng
Publication year - 2011
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.21950
Subject(s) - clenbuterol , myostatin , endocrinology , medicine , muscle hypertrophy , anabolism , phosphorylation , skeletal muscle , wasting , myocyte , protein kinase b , transgene , chemistry , biology , biochemistry , gene
In this study we investigated the combined effect of myostatin (MSTN) suppression and β‐agonist (clenbuterol) administration on muscle hypertrophy and the phosphorylation of muscle 4E‐BP1 and p70S6k, two downstream effectors of the Akt/mTOR anabolic pathway. Methods: Female heterozygous MSTN‐prodomain transgenic mice (an MSTN suppression model) and wild‐type littermates were given 0 or 20 ppm of clenbuterol (CL) in their drinking water, and muscle samples were collected at 1 and 2 weeks after treatment. Results: CL increased body and muscle mass in both genotypes. Levels of phosphorylated muscle 4E‐BP1 and p70S6k were higher in MSTN‐prodomain transgenic mice than in wild‐type mice. CL increased the phosphorylation of 4E‐BP1 and p70S6k in both genotypes. Conclusions: The muscle‐hypertrophic effect of CL is additive to the effect of MSTN suppression. The combination of MSTN suppression and treatment with β‐agonists may be an effective therapeutic approach to combat muscle‐wasting conditions. Muscle Nerve, 2011